| P2093 | author name string | M C Santais | |
| | F Ruff | |
| | E Callens | |
| | R Djebbar | |
| P2860 | cites work | Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis | Q24299373 |
| | The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock | Q24537753 |
| | Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist | Q28322631 |
| | Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and Inflammation | Q34254403 |
| | Liberation of histamine and formation of lysocithin-like substances by cobra venom | Q34568156 |
| | Arachidonic acid metabolism in airway epithelial cells | Q35994872 |
| | Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses | Q36573372 |
| | Leukotriene receptor antagonists as potential therapeutic agents | Q38272493 |
| | The signal transduction system of the leukotriene D4 receptor | Q38310931 |
| | Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. | Q39473939 |
| | Clinical implications of prostaglandin and thromboxane A2 formation (1). | Q39519424 |
| | Cysteinyl leukotrienes in asthma: old mediators up to new tricks | Q40372475 |
| | Leukotrienes as therapeutic target in asthma | Q40383957 |
| | Leukotrienes as a target in asthma therapy | Q40387180 |
| | Prostanoids and leukotrienes in rheumatoid synovitis | Q40566313 |
| | 5-Lipoxygenase activation in psoriasis: a dead issue? | Q40759855 |
| | Reduced Allergen-Induced Nasal Congestion and Leukotriene Synthesis with an Orally Active 5-Lipoxygenase Inhibitor | Q41137843 |
| | Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. | Q41199570 |
| | A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma | Q41273463 |
| | Cysteinyl leukotriene receptors in the human lung: what's new? | Q41287867 |
| | 2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity | Q41821910 |
| | Selective chiral inhibitors of 5-lipoxygenase with anti-inflammatory activity | Q41965832 |
| | Leukotrienes in the sputum and urine of cystic fibrosis children | Q41972684 |
| | Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor | Q42283561 |
| | Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group | Q42284265 |
| | Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction | Q42288898 |
| | Release of leukotrienes in patients with bronchial asthma | Q43414768 |
| | Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome | Q44696586 |
| | Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response | Q45075371 |
| | Sulphidopeptide leukotrienes in asthma | Q46189427 |
| | MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human | Q49122118 |
| | Attenuation of inhaled allergen-induced airway microvascular leakage and airflow obstruction in guinea pigs by a 5-lipoxygenase inhibitor (A-63162). | Q50803915 |
| | Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine. | Q54312688 |
| | THE LIBERATION OF A SLOW-REACTING SMOOTH MUSCLE-STIMULATING SUBSTANCE IN ANAPHYLAXIS | Q56432304 |
| | The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin | Q57240791 |
| | Identification and isolation of a membrane protein necessary for leukotriene production | Q59059824 |
| | Pustular psoriasis and aseptic purulent arthritis: possible role of leukotrienes B4 and C4 in a flare of synovitis. | Q64976817 |
| | Urinary leukotriene E after exercise challenge in children with asthma | Q67490125 |
| | Recovery of Leukotriene E4from the Urine of Patients with Airway Obstruction | Q67491764 |
| | Urinary Excretion of Leukotriene E4and 11-dehydro-Thromboxane B2in Response to Bronchial Provocations with Allergen, Aspirin, Leukotriene D4, and Histamine in Asthmatics | Q67491772 |
| | Urinary leukotriene E4 excretion in exercise-induced asthma | Q67504515 |
| | Urinary Leukotriene E4Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects | Q67915846 |
| | Plasma elevations of histamine and a prostaglandin metabolite in acute asthma | Q67976033 |
| | The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma | Q68026345 |
| | Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma | Q68265058 |
| | Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects | Q68293935 |
| | The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air | Q68613879 |
| | Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis | Q69367977 |
| | Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects | Q69829869 |
| | Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid | Q69886676 |
| | Characterisation of the peptido-leukotriene receptor PL2 on the ferret spleen strip | Q70493732 |
| | Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078 | Q72047221 |
| | The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma | Q72204968 |
| | Leukotriene E4 and granulocytic infiltration into asthmatic airways | Q72215711 |
| | The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma | Q72605042 |
| | Eicosanoid production by the mucosa in inflammatory bowel disease after 5-ASA treatment | Q72795622 |
| | Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans | Q72970802 |
| P433 | issue | 2 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 98-107 | |
| P577 | publication date | 1998-02-01 | |
| P1433 | published in | Revue de Médecine Interne | Q3428665 |
| P1476 | title | [Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class] | |
| P478 | volume | 19 | |